{'52WeekChange': -0.16414583,
 'SandP52WeekChange': None,
 'address1': 'Building 300',
 'address2': 'Suite 201 One Kendall Square',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 20,
 'askSize': 1100,
 'averageDailyVolume10Day': 194062,
 'averageVolume': 341328,
 'averageVolume10days': 194062,
 'beta': 1.717804,
 'beta3Year': None,
 'bid': 18.27,
 'bidSize': 1100,
 'bookValue': 7.124,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 18.69,
 'dayLow': 17.89,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.783,
 'enterpriseToRevenue': None,
 'enterpriseValue': 400634720,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 19.494858,
 'fiftyTwoWeekHigh': 29.32,
 'fiftyTwoWeekLow': 9.76,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 29342851,
 'forwardEps': -3.22,
 'forwardPE': -5.6770186,
 'fromCurrency': None,
 'fullTimeEmployees': 112,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.02797,
 'heldPercentInstitutions': 0.83668,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/avrobio.com',
 'longBusinessSummary': 'AVROBIO, Inc., a clinical-stage gene therapy company, '
                        'focuses on developing ex vivo lentiviral-based gene '
                        'therapies to treat rare diseases following a single '
                        'dose in the United States. Its gene therapies employ '
                        'hematopoietic stem cells that are collected from '
                        'patients and modified with a lentiviral vector to '
                        'insert functional copies of the gene, which is '
                        "defective in the target disease. The company's lead "
                        'product candidate is AVR-RD-01, which is in ongoing '
                        'Phase II clinical trial and investigator-sponsored '
                        'Phase I clinical trial for the treatment of Fabry '
                        'disease. It is also developing AVR-RD-02 that has '
                        'completed pre-clinical trials for the treatment of '
                        'type 1 Gaucher disease; AVR-RD-03, which is in '
                        'preclinical development to treat Pompe disease; and '
                        'AVR-RD-04 that has completed pre-clinical studies for '
                        'treating cystinosis. The company has a research and '
                        'clinical collaboration agreement with Magenta '
                        'Therapeutics to evaluate targeted antibody-drug '
                        'conjugate as a conditioning regimen for lentiviral '
                        'gene therapies. AVROBIO, Inc. was founded in 2015 and '
                        'is headquartered in Cambridge, Massachusetts.',
 'longName': 'AVROBIO, Inc.',
 'market': 'us_market',
 'marketCap': 658728960,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_326042490',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -81835000,
 'nextFiscalYearEnd': 1640908800,
 'open': 18.69,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-914-8420',
 'previousClose': 18.79,
 'priceHint': 2,
 'priceToBook': 2.5659742,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 18.69,
 'regularMarketDayLow': 17.89,
 'regularMarketOpen': 18.69,
 'regularMarketPreviousClose': 18.79,
 'regularMarketPrice': 18.69,
 'regularMarketVolume': 179062,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 36035500,
 'sharesPercentSharesOut': 0.0668,
 'sharesShort': 2408173,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1725647,
 'shortName': 'AVROBIO, Inc.',
 'shortPercentOfFloat': 0.0787,
 'shortRatio': 5.81,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'AVRO',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.739,
 'twoHundredDayAverage': 18.292734,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a532199a-b6ec-3584-8874-430070002ccb',
 'volume': 179062,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.avrobio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}